Cargando…

The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancer

BACKGROUND: The Stop&Go study randomized patients with advanced breast cancer to intermittent (two times four) or continuous (eight subsequent cycles) first- and second-line chemotherapy. METHODS: QoL was measured with RAND-36 questionnaires every 12 weeks. The primary objective was to estimate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Claessens, Anouk K. M., Timman, Reinier, Busschbach, Jan J., Bouma, Jeanette M., Rademaker-Lakhai, Jeany M., Erdkamp, Frans L. G., Tjan-Heijnen, Vivianne C. G., Bos, Monique E. M. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2019
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997247/ https://www.ncbi.nlm.nih.gov/pubmed/31782032 http://dx.doi.org/10.1007/s10549-019-05495-3

Ejemplares similares

Different outcome in node-positive breast cancer patients found by axillary ultrasound or sentinel node procedure
por: Verheuvel, Nicole C., et al.
Publicado: (2017)

The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry
por: Meegdes, Marissa, et al.
Publicado: (2022)

Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial
por: van Hellemond, Irene E. G., et al.
Publicado: (2020)

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy
por: Hurvitz, Sara A., et al.
Publicado: (2013)

Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial
por: Sonke, Gabe S., et al.
Publicado: (2017)

The influence of neoadjuvant chemotherapy on complications of immediate DIEP flap breast reconstructions
por: Beugels, J., et al.
Publicado: (2019)

The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2− advanced breast cancer patients: A study of the Dutch SONABRE Registry
por: Meegdes, Marissa, et al.
Publicado: (2021)

Logical inconsistencies in time trade-off valuation of EQ-5D-5L health states: Whose fault is it?
por: Yang, Zhihao, et al.
Publicado: (2017)

Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer
por: Vriens, B. E. P. J., et al.
Publicado: (2017)

The clinical impact of molecular breast imaging in women with proven invasive breast cancer scheduled for breast-conserving surgery
por: Collarino, Angela, et al.
Publicado: (2018)

Preserving fertility in young women undergoing chemotherapy for early breast cancer; the Maastricht experience
por: Vriens, Ingeborg J. H., et al.
Publicado: (2020)

SF-6D utility values for the better- and worse-seeing eye for health states based on the Snellen equivalent in patients with age-related macular degeneration
por: Visser, Martijn S., et al.
Publicado: (2017)

Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study
por: Lynce, F., et al.
Publicado: (2019)

An evaluation of four modes of low-dose anticoagulation during intermittent haemodialysis
por: Skagerlind, Malin S. E., et al.
Publicado: (2017)

Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer
por: van Hellemond, Irene E. G., et al.
Publicado: (2018)

Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry
por: Ibragimova, Khava I. E., et al.
Publicado: (2023)

Six and eight weeks injection frequencies of bevacizumab are non-inferior to the current four weeks injection frequency for quality of life in neovascular age-related macular degeneration: a randomized controlled trial
por: Visser, Martijn S., et al.
Publicado: (2020)

Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry
por: Ibragimova, Khava I. E., et al.
Publicado: (2021)

HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
por: Kurozumi, Sasagu, et al.
Publicado: (2016)

EndoPredict(®) in early hormone receptor-positive, HER2-negative breast cancer
por: Almstedt, K., et al.
Publicado: (2020)

Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
por: Chen, Zhaoxu, et al.
Publicado: (2023)

The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer
por: Bardia, Aditya, et al.
Publicado: (2022)

Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry
por: Meegdes, Marissa, et al.
Publicado: (2023)

What to Do with Non-visualized Sentinel Nodes? A Dutch Nationwide Survey Study
por: Verheuvel, Nicole C., et al.
Publicado: (2017)

Effects of Community-based Exercise Prehabilitation for Patients Scheduled for Colorectal Surgery With High Risk for Postoperative Complications: Results of a Randomized Clinical Trial
por: Berkel, Annefleur E. M., et al.
Publicado: (2022)

A very short version of the Visual Function Questionnaire (VFQ‐3oo7) for use as a routinely applied Patient‐Reported Outcome Measure
por: Visser, Martijn S., et al.
Publicado: (2020)

HER2-targeted therapy influences CTC status in metastatic breast cancer
por: Deutsch, Thomas M., et al.
Publicado: (2020)

Long-term effects of a three-component lifestyle intervention on emotional well-being in women with Polycystic Ovary Syndrome (PCOS): A secondary analysis of a randomized controlled trial
por: Jiskoot, Geranne, et al.
Publicado: (2020)

Weight Reduction Through a Cognitive Behavioral Therapy Lifestyle Intervention in PCOS: The Primary Outcome of a Randomized Controlled Trial
por: Jiskoot, Geranne, et al.
Publicado: (2020)

Changes in eating behavior through lifestyle treatment in women with polycystic ovary syndrome (PCOS): a randomized controlled trial
por: Jiskoot, Geranne, et al.
Publicado: (2022)

Lifestyle treatment in women with polycystic ovary syndrome: predictors of weight loss and dropout
por: Jiskoot, Geranne, et al.
Publicado: (2022)

Quality of life in a real-world cohort of advanced breast cancer patients: a study of the SONABRE Registry
por: Claessens, Anouk K. M., et al.
Publicado: (2020)

The development of the DISCO-RC for measuring children’s discomfort during research procedures
por: Staphorst, Mira S., et al.
Publicado: (2017)

Detection of circulating tumor cells and circulating tumor DNA before and after mammographic breast compression in a cohort of breast cancer patients scheduled for neoadjuvant treatment
por: Förnvik, Daniel, et al.
Publicado: (2019)

A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2013)

Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens
por: Moy, Beverly, et al.
Publicado: (2021)

Predicting the outcome of a cognitive-behavioral group training for patients with unexplained physical symptoms: a one-year follow-up study
por: Zonneveld, Lyonne NL, et al.
Publicado: (2012)

Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer
por: Denys, Hannelore, et al.
Publicado: (2020)

A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study
por: Lidbrink, Elisabet, et al.
Publicado: (2018)

Frequency and diagnostic outcome of bilateral recall at screening mammography
por: Lameijer, Joost R. C., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5s2sljgsnsbfuugfurtjg25762